INO · Inovio Pharmaceuticals Inc
United States · RS rating 89 · As of 2026-11-03
| Price | 1.66 USD |
|---|---|
| 1-day change | -12.2% |
| RS rating (overall / 1M / 3M / 12M) | 89 / 98 / 97 / 31 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 54 / 34 / 65 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +75.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +36.1% |
| Market cap (USD) | $93.0M |